MODULATION OF THE SYSTEM IN SEROTONINERGIC PARKINSON'S DISEASE: THERAPEUTIC APPLICATIONS IN BASIC AND CLINICAL RESEARCH
Resumo
Serotonin, also called 5-hydroxytryptamine is a neurotransmitter synthesized from dietary tryptophan regulatory having high potential in human tissues. 5-HT can act as a neurotransmitter in nerve fibers of fixed catalyst homeostatic responses and central nervous system can control cognition, emotion and motor behavior. The present study is an investigation of the main applications and intervene. Therapeutic enções described in publications about the serotonergic modulation in patients with Parkinson's disease in different stages as well as the experimental animal studies induced parkinsonism. The study leads to an update of the main therapeutic targets as serotonin transporter, serotonin receptor tissue, among others.
Palavras-chave
Texto completo:
PDF (English)Referências
ALBIN RL et al. Spared Flow Brainstem SERT Binding in Early Parkinson's Disease. Journal Of Cerebral Blood Flow & Metabolism, [sl], v. 28, no. 3, p.441-444 12 December 2007 SAGE Publications.http://dx.doi.org/10.1038/sj.jcbfm.9600599.
AZMITIA, EC. Serotonin and Brain: Evolution, Neuroplasticity, and Homeostasis. International Review Of Neurobiology, [sl], p.31-56, 2007. Elsevier.http://dx.doi.org/10.1016/s0074-7742(06)77002-7.
BARRETT, KE et al. Neurotransmitters & neuromodulators. In: BARRETT, KE et al. Ganong's Review of Medical Physiology. 24. ed. Mcgraw-hill, 2019. Chap. 7. p. 334-377.
BEDARD, C. et al. Serotonin and dopamine striatal innervation in Parkinson's disease and Huntington's chorea. Parkinsonism & Related Disorders, [SL], v. 17, no. 8, p.593-598 set. 2011. Elsevier BV.http://dx.doi.org/10.1016/j.parkreldis.2011.05.012.
BERGER, M .; GRAY, JA; ROTH, BL The Expanded Biology of Serotonin. Annual Review of Medicine, [SL], v. 60, no. 1, p.355-366, Feb. 2009. Annual Reviews.http://dx.doi.org/10.1146/annurev.med.60.042307.110802.
BERGHAUZEN-MACIEJEWSKA, K. et al. Adaptive down-regulation of the serotonin transporter in the 6-hydroxydopamine-induced rat model of preclinical stages of Parkinson's disease and after chronic treatment pramipexole. Neuroscience, [sl], v. 314, p.22-34, Feb. 2016 Elsevier BV.http://dx.doi.org/10.1016/j.neuroscience.2015.11.049.
CARLSSON, T. et al. Serotonin Neuron Transplants exacerbate L-Induced dopaminergic DYSKINESIAS in a Rat Model of Parkinson's Disease. Journal Of Neuroscience, [sl], v. 27, no. 30, p.8011-8022, July 25. 2007 Society for Neuroscience.http://dx.doi.org/10.1523/jneurosci.2079-07.2007.
CAMPOS, ACP et al. Monoaminergic regulation of nociceptive circuitry in Parkinson's disease rat model. Experimental Neurology, [sl], v. 318, p.12-21, aug. 2019. Elsevier BV.http://dx.doi.org/10.1016/j.expneurol.2019.04.015.
CAO, L. et al. Restoring Spinal Noradrenergic Inhibitory Tone Attenuates Pain Hypersensitivity in a Rat Model of Parkinson's Disease. Neural Plasticity, [s.l.], v. 2016, p.1-16, 2016. Hindawi Limited. http://dx.doi.org/10.1155/2016/6383240.
LETTER, M. et al. Role of serotonin neurons in the induction of levodopa- and graft-induced DYSKINESIAS in Parkinson's disease. Movement Disorders, [sl], v. 25, no. 1, p.174-179, Wiley 2010.http://dx.doi.org/10.1002/mds.22792.
CREED, RB et al. Basal and Evoked Levels in Neurotransmitter Parkin, DJ-1, PINK1 and LRRK2 Knockout Rat Striatum. Neuroscience, [sl], v. 409, p.169-179, jun. 2019. Elsevier BV.http://dx.doi.org/10.1016/j.neuroscience.2019.04.033.
DAVID DJ; GARDIER, AM. Les pharmacologie bases fondamentale du système sérotoninergique: application à la réponse antidepressive. L'encéphale, [sl], v. 42, no. 3, p.255-263, jun. 2016 Elsevier BV.http://dx.doi.org/10.1016/j.encep.2016.03.012.
ISHII; KINOSHITA; MUROI. Serotonin 5-HT4 Receptor Agonists Improve Facilitation of Contextual Fear Extinction An in MPTP-Induced Mouse Model of Parkinson's Disease. International Journal of Molecular Sciences, [SL], v. 20, no. 21, p.1-12 26 October 2019 MDPI AG.http://dx.doi.org/10.3390/ijms20215340.
ISOOKA, N. et al. Dopaminergic neuroprotective effects of rotigotine through 5-HT1A receptors: Possibly Involvement of metallothionein expression in astrocytes. Neurochemistry International, [sl], v. 132, p.1-13, Jan. 2020 Elsevier BV.http://dx.doi.org/10.1016/j.neuint.2019.104608.
KISH SJ et al. Preferential loss of serotonin markers in caudate putamen versus in Parkinson's disease. Brain, [sl], p.120-131 22 October 2007. Oxford University Press (OUP).http://dx.doi.org/10.1093/brain/awm239.
KWAN, C .; HUOT, P. 5-HT3 receptors psychosis in Parkinson's disease: a target forgotten ?. Neurodegenerative Disease Management, [sl], v. 9, no. 5, p.251-253, may. 2019. Future Medicine Ltd.http://dx.doi.org/10.2217/nmt-2019-0014.
LEAL, PC et al. Serotonergic dysfunction in a model of parkinsonism induced by reserpine. Journal Of Chemical Neuroanatomy, [sl], v. 96, p.73-78, sea. 2019. Elsevier BV.http://dx.doi.org/10.1016/j.jchemneu.2018.12.011
LI, M. et al. Sensation of TRPV1 via the 5-hydroxytryptamine pain hypersensitivity modulates signaling in the 6-hydroxydopamine induced mice model of Parkinson's disease. And Biochemical Biophysical Research Communications, [sl], p.1-6, Nov.. 2019. Elsevier BV.http://dx.doi.org/10.1016/j.bbrc.2019.10.204.
LI, Y. et al. Investigation of Behavioral Dysfunctions Induced by Monoamine depletions in Mouse Model of Parkinson's Disease. Frontiers In Cellular Neuroscience, [sl], v. 12, p.1-13 8 August 2018. Frontiers Media SA.http://dx.doi.org/10.3389/fncel.2018.00241.
LIAN, T. et al. An Investigation on the Clinical Features and Neurochemical Changes in Parkinson's Disease With Depression. Frontiers In Psychiatry, [sl], v. 9, p.1-9, January 18. 2019. Frontiers Media SA.http://dx.doi.org/10.3389/fpsyt.2018.00723.
LIU, KC et al. Activation and blockade of dorsal hippocampal receptors Serotonin6 anxiety-like behaviors regulate in a unilateral 6-hydroxydopamine rat model of Parkinson's disease. Neurological Research, [SL], v. 41, no. 9, p.791-801, May 6 2019. Informa UK Limited.http://dx.doi.org/10.1080/01616412.2019.1611204.
LIU, KC et al. Activation and blockade of serotonin6 receptors in the dorsal hippocampus Enhance T maze and hole-board performance in a unilateral 6-hydroxydopamine rat model of Parkinson's disease. Brain Research, [sl], v. 1650, p.184-195, Nov.. 2016 Elsevier BV.http://dx.doi.org/10.1016/j.brainres.2016.09.009.
MAEDA, T. et al. Serotonergic hyperinnervation into the dopaminergic denervated striatum dopamine compensates for conversion from exogenously administered L-DOPA. Brain Research, [sl], v. 1046, no. 1-2, p.230-233, jun. 2005 Elsevier BV.http://dx.doi.org/10.1016/j.brainres.2005.04.019.
MILLOT, M. et al. Prior MDMA administration aggravates MPTP-induced Parkinsonism in monkeys macaque. Neurobiology Of Disease, [sl], v. 134, p.1-9, Feb. 2020 Elsevier BV.http://dx.doi.org/10.1016/j.nbd.2019.104643.
MOHAMMAD-ZADEH, LF; MOSES, L .; Gwaltney-BRANT, SM Serotonin: a review. Journal of Veterinary Pharmacology and Therapeutics, [SL], v. 31, no. 3, p.187-199, jun. Wiley 2008.http://dx.doi.org/10.1111/j.1365-2885.2008.00944.x
NASRALLAH, HA; FEDORA, R .; MORTON, R. Successful treatment of clozapine-nonresponsive hallucinations and delusions refractory pimavanserin with the serotonin 5HT 2A receptor inverse-agonist. Schizophrenia Research, [SL], v. 208, p.217-220, jun. 2019. Elsevier BV.http://dx.doi.org/10.1016/j.schres.2019.02.018.
NICHOLS, DE; NICHOLS, CD Serotonin Receptors. Chemical Reviews, [sl], v. 108, no. 5, p.1614-1641, May 2008. American Chemical Society (ACS).http://dx.doi.org/10.1021/cr078224o.
OOSTERWIJK, CS et al. Anxiety in Parkinson's disease is associated with reduced structural covariance of the striatum. Journal Of Affective Disorders, [sl], v. 240, p.113-120, Nov.. 2018 Elsevier BV.http://dx.doi.org/10.1016/j.jad.2018.07.053
PADOVAN-NETO, FE et al. Regulation of Selective Serotonin 5-HT1B Receptor Expression in the striatum Dopamine depletion by L-DOPA and Repeated Treatment: Relationship to L-DOPA-induced DYSKINESIAS. Molecular Neurobiology, [sl], p.1-16 Aug. 29. 2019. Springer Science and Business Media LLC.http://dx.doi.org/10.1007/s12035-019-01739-x.
PASQUINI, J. et al. Progressive loss of raphe nuclei serotonin transporter in early Parkinson's disease: The longitudinal 123I-FP-CIT SPECT study. Parkinsonism & Related Disorders, [sl], p.1-6, abr. 2019. Elsevier BV.http://dx.doi.org/10.1016/j.parkreldis.2019.03.025.
POLITIS, M.; LOANE C. Serotonergic Dysfunction in Parkinson's Disease and Its Relevance to Disability. The Scientific World Journal, [sl], v. 11, p.1726-1734, 2011. Hindawi Limited.http://dx.doi.org/10.1100/2011/172893.
POLITIS, M.; NICCOLINI, F. Serotonin in Parkinson's disease. Behavioral Brain Research, [sl], v. 277, p.136-145, Jan. 2015 Elsevier BV.http://dx.doi.org/10.1016/j.bbr.2014.07.037.
RYAN, M .; EATMON, CV; SLEVIN, JT. Drug treatment strategies in Parkinson's disease is depression. Expert Opinion On Pharmacotherapy, [sl], v. 20, no. 11, p.1351-1363, May 23 2019. Informa UK Limited.http://dx.doi.org/10.1080/14656566.2019.1612877.
SOMAN, S.; BHATTACHARYA, A.; PANICKER MM. Dopamine residues requires unique to signal via the serotonin 2A receptor. Neuroscience, [sl], p.1-13, abr. 2019. Elsevier BV.http://dx.doi.org/10.1016/j.neuroscience.2019.03.056.
TEISSIER, A.; SOIZA-REILLY, M.; CASPAR, P. Refining The role of 5-HT in Postnatal Development of Brain Circuits. Frontiers In Cellular Neuroscience, [sl], v. 11, p.1-9, 23 May 2017. Frontiers Media SA.http://dx.doi.org/10.3389/fncel.2017.00139.
VIEIRA, JCF et al. Anxiety-like behavior induced by 6-OHDA animals model of Parkinson's disease may be related to the dysregulation of neurotransmitter systems in brain areas related to anxiety. Behavioral Brain Research, [sl], v. 371, p.1-6, may. 2019. Elsevier BV.http://dx.doi.org/10.1016/j.bbr.2019.111981.
WALKER, M. et al. Imaging SERT Availability in the Rat Model of L-DOPA-induced Dyskinesia. Molecular Imaging and Biology, [sl], p.1-9 8 August 2019. Springer Science and Business Media LLC.http://dx.doi.org/10.1007/s11307-019-01418-2.
WIHAN, J. et al. Layer-specific axonal degeneration of serotonergic fibers in the prefrontal cortex of aged α-synuclein A53T-expressing mice. Neurobiology Of Aging, [sl], v. 80, p.29-37, aug. 2019. Elsevier BV.http://dx.doi.org/10.1016/j.neurobiolaging.2019.03.014.
WILE, D. J. et al. Serotonin and dopamine transporter PET changes in the premotor phase of LRRK2 parkinsonism: Cross-sectional studies. The Lancet Neurology, [sl], v. 16, no. 5, p.351-359, May 2017. Elsevier BV.http://dx.doi.org/10.1016/s1474-4422(17)30056-x.
WILSON, H. et al. Serotonergic pathology and disease burden in the phase motor and premotor of α-synuclein A53T parkinsonism: cross-sectional study. The Lancet Neurology, [sl], v. 18, no. 8, p.748-759, August. 2019. Elsevier BV.http://dx.doi.org/10.1016/s1474-4422(19)30140-1.
YUAN et al. Activation and Blockade of serotonin4 receptors in the working memory Improve habenula side in unilateral 6-hydroxydopamine-lesioned rats Parkinson's, Neurological Research, 2019.https://doi.org/10.1080/01616412.2019.1596055
WU, H. et al. Beyond a neurotransmitter: The role of serotonin in inflammation and immunity. Pharmacological Research, [SL], v. 140, p.100-114, Feb. 2019. Elsevier BV.http://dx.doi.org/10.1016/j.phrs.2018.06.015
Apontamentos
- Não há apontamentos.
Revista Brasileira de Neurologia e Psiquiatria. ISSN: 1414-0365